Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Assets (2016 - 2026)

Mimedx's Assets history spans 17 years, with the latest figure at $308.7 million for Q1 2026.

  • On a quarterly basis, Assets rose 14.15% to $308.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $308.7 million, a 14.15% increase, with the full-year FY2025 number at $342.7 million, up 29.83% from a year prior.
  • Assets hit $308.7 million in Q1 2026 for Mimedx, down from $342.7 million in the prior quarter.
  • Over the last five years, Assets for MDXG hit a ceiling of $342.7 million in Q4 2025 and a floor of $168.2 million in Q1 2023.
  • Historically, Assets has averaged $232.4 million across 5 years, with a median of $230.2 million in 2024.
  • Biggest five-year swings in Assets: decreased 9.87% in 2022 and later soared 39.44% in 2023.
  • Tracing MDXG's Assets over 5 years: stood at $171.4 million in 2022, then surged by 39.44% to $239.0 million in 2023, then increased by 10.4% to $263.9 million in 2024, then increased by 29.83% to $342.7 million in 2025, then fell by 9.92% to $308.7 million in 2026.
  • Business Quant data shows Assets for MDXG at $308.7 million in Q1 2026, $342.7 million in Q4 2025, and $319.0 million in Q3 2025.